that, they say, is why they seek an additional order requiring disclosure by vip of all customers to whom vip sold cb1 type ibcs as previously defined.
in light of the defective compliance by vip with the norwich pharmacal order (which followed an earlier error on affidavit in relation to schutz 2), i would discount the costs order in its favour.
the question is whether schutz have advanced any evidence to show any new risk.